How Sensitive Are Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Gene–Sensitive Mutations?

Journal of Thoracic Oncology- United States

doi 10.1097/jto.0000000000000098

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor

JAMA - Journal of the American Medical Association
Medicine
2014English

MA27.07 Lung Adenocarcinoma Harboring BRAF G469V Mutation Is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinical Characteristics and Response to Tyrosine Kinase Inhibitors of Patients With Non-Small Cell Lung Cancer Harboring Uncommon Epidermal Growth Factor Receptor Mutations

Chinese Journal of Cancer Research
Cancer ResearchOncology
2017English

Epidermal Growth Factor Receptor (EGFR) Mutations and Expression in Squamous Cell Carcinoma of the Esophagus in Central Asia

BMC Cancer
Cancer ResearchOncologyGenetics
2012English

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients With Advanced Non-Small Cell Lung Cancer

Current Gerontology and Geriatrics Research
GerontologyGeriatrics
2010English

The Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

2013English

Association of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment and EGFR Exon 19 Deletion With Frequency of the T790M Mutation in Non-Small Cell Lung Cancer Patients After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

OncoTargets and Therapy
OncologyPharmacology
2019English

Impact of Epidermal Growth Factor Receptor Gene Expression Level on Clinical Outcomes in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Patients Taking First-Line Epidermal Growth Factor Receptor–tyrosine Kinase Inhibitors

Tumor Biology
MedicineCancer Research
2017English

Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Recurrent Adenosquamous Carcinoma of the Lung After Resection

OncoTargets and Therapy
OncologyPharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy